Clinical Trial

A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours

Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to determine the appropriate dosage, safety and effectiveness of the study drug, IPN01194 in adults with advanced solid tumours. The participants in this study will have advanced solid tumours. 'Advanced solid tumours' refers to cancers that can occur in several places, including cancers in organs or tissues that have spread from their original site to nearby tissues or other parts of the body. In this study, all participants will receive the study drug, which will be taken by mouth (orally).
Protocol Amendment History 2 changes
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-05-21
notable Enrollment reduced: 220 -> 36 participants 2026-05-21
Trial Details
NCT Number NCT06305247
Lead Sponsor Ipsen
Conditions Melanoma, Head and Neck Squamous Cell Carcinoma, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Solid Tumor
Enrollment 36 participants
Start Date 2024-04-03
Primary Completion 2028-03-20 (estimated)
Study Completion 2028-03-20 (estimated)
Updated on ClinicalTrials.gov 2026-07-30